Fintel reports that on November 13, 2024, HC Wainwright & Co. downgraded their outlook for Syros Pharmaceuticals ...

Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Syros Pharmaceuticals Inc (NASDAQ:SYRS) is advancing tamibarotene as a potential new standard of care for higher-risk MDS patients with RARA overexpression, targeting a significant unmet medical need.

Syros Pharmaceuticals ( (SYRS) ) has released its Q3 earnings. Here is a breakdown of the information Syros Pharmaceuticals presented to its ...

Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Note that this call is being ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Syros Pharmaceuticals (NASDAQ:SYRS) files a $250 million mixed securities shelf. The company may sell:Debt SecuritiesCommon StockPreferred StockUnitsWarrant ...

H.C. Wainwright has recently raised Syros Pharmaceuticals Inc (SYRS) stock to Buy rating, as announced on November 4, 2020, according to Finviz. Earlier, on September 22, 2020, Alliance Global ...